Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q1 2024 · 10-Q
Revenue$10.18M$10.18M+5.4% vs Q1 2023 Net Income$708.00K$708.00K+37.7% vs Q1 2023 EPS Diluted$0.16$0.16+33.3% vs Q1 2023 Gross Profit$6,311,000+2.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flow-$58,000N/M Free Cash Flowderived-$86,000N/M Margins · derivedGross margin62.0%−1.6 pt vs Q1 2023
Operating margin10.9%+2.3 pt vs Q1 2023
Net margin7.0%+1.6 pt vs Q1 2023
ended Mar 31, 2024 · filed May 9, 2024 · 39 d after period end